Evaluation of an AI-Assisted Tool for CLABSI Surveillance at VA Medical Centers
NCT07918352, Not applicable, Not yet recruiting, University of Maryland, Baltimore
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluation of an AI-Assisted Tool for CLABSI Surveillance at VA Medical Centers | ClinicalTrials.gov |
| NCT number | NCT07918352 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 30 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Maryland, Baltimore | ClinicalTrials.gov |
| Conditions | Central Line-Associated Bloodstream Infection (CLABSI), Bacteremia, Bloodstream Infections | ClinicalTrials.gov |
| Interventions | Generative AI tool for CLABSI surveillance | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Time per bacteremia case review | At completion of each bacteremia case review performed during the study period beginning 1 month prior to implementation until 6 months post-implementation. | Time in elapsed minutes captured automatically by start and end time of the per-case review form. Assessed at time of completion of the bacteremia case review. | ClinicalTrials.gov |
| Secondary | Difficulty of bacteremia case review | At completion of each bacteremia case review performed during the study period beginning 1 month prior to implementation until 6 months post-implementation. | Measured using the Single Ease Question, a validated single-item 7-level scale. | ClinicalTrials.gov |
| Secondary | Objectivity of case review | At completion of each bacteremia case review performed during the study period beginning 1 month prior to implementation until 6 months post-implementation. | Measured using a question on the case review form ("How objective is the case to review? (1=not at all objective to 7=very objective)"). | ClinicalTrials.gov |
| Secondary | Reviewer confidence in case review | At completion of each bacteremia case review performed during the study period beginning 1 month prior to implementation until 6 months post-implementation. | Measured using a question on the case review form ("How confident are you with your review of this case? (1=not confident to 7=very confident)"). | ClinicalTrials.gov |
| Secondary | Infection preventionist-identified safety problems | Assessed monthly during each facility's 6-month post-implementation period | Reported using a binary question (yes/no) on the monthly survey administered to all sites during the post-implementation period. | ClinicalTrials.gov |
| Secondary | Infection preventionist-identified direct patient harm | Assessed monthly during each facility's 6-month post-implementation period | Reported using a binary question (yes/no) on the monthly survey administered to all sites during the post-implementation period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)